Crossmark

Abuse and dependence potential of sphingosine-1-phosphate (S1P) receptor modulators used in the treatment of multiple sclerosis: a review of literature and public data

Crossref DOI link: https://doi.org/10.1007/s00213-021-06011-6

Published Online: 2021-11-13

Published Print: 2022-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Schoedel, Kerri A.

Kolly, Carine

Gardin, Anne

Neelakantham, Srikanth

Shakeri-Nejad, Kasra
Funding

Funding for this research was provided by:

Novartis Pharma AG, Switzerland (Funding for the editorial support)
License Information

Text and Data Mining valid from 2021-11-13

Version of Record valid from 2021-11-13
More Information

Article History

Received: 6 January 2021

Accepted: 18 October 2021

First Online: 13 November 2021

Declarations

:

: The authors did not receive payment for the preparation of the article; however, Dr. Schoedel provides consulting services to Novartis Pharma AG and other pharmaceutical companies. Dr. Kolly, Dr. Gardin, Mr. Neelakantham, and Dr. Shakeri-Nejad are employees of Novartis.

Document is current

Any future updates will be listed below